Comparable stake leader
Lynx1 Capital Management LP
SEC ownership of Passage BIO, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001787297.
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
36/50
Latest evidence
25 Jun 2026
- Public ticker
- PASG on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lynx1 Capital Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
36 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lynx1 Capital Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
25 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001787297
- Issuer location
- Philadelphia, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Passage BIO, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
36/50
Latest evidence
25 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 21%
14 rows are not safely comparable across share classes.
13D/G row: Lynx1 Capital Management LP
Showing 1-8 of 50 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 21%.
36 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
21%
Baselake Partners, LP
7.3%
Erste Asset Management GmbH
4.4%
ORBIMED ADVISORS LLC
4.2%
Weston Nichols
21%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
21%
from 13D/G
|
$4,896,076
623,704 shares
|
— | 31 Mar 2026 |
| Baselake Partners, LP |
13D/G
|
7.3%
|
$1,203,497
235,058 shares
|
$0 | 18 Jun 2026 |
| Erste Asset Management GmbH |
13D/G
13F
Company
|
4.4%
|
$810,414
2,455,800 shares
|
-$166,650 | 31 Mar 2024 |
| ORBIMED ADVISORS LLC |
3/4/5
13D/G
10%+ Owner
|
4.2%
from 13D/G
|
$2,001,893
6,066,343 shares
|
— | 24 Jun 2025 |
| Weston Nichols |
3/4/5
10%+ Owner
|
21%
|
$2,774,202
673,759 shares
|
+$206,101 | 25 Jun 2026 |
| Vestal Point Capital, LP |
13F
Company
|
9.5%
|
$2,394,250
305,000 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
4.1%
|
$1,048,854
133,612 shares
|
— | 31 Mar 2026 |
| Eversept Partners, LP |
13F
Company
|
4.1%
|
$1,032,911
131,581 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$635,938.
Buys
$635,938
Insiders: 2
Sells
$0
Insiders: 0
Net
+$635,938
Shares: +132,118
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 132,118
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 100,110 | 0 | $412,203 | $0 | +$412,203 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 32,008 | 0 | $223,735 | $0 | +$223,735 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to Passage BIO, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Weston Nichols
Net 12M change
+$635,937
Latest report
25 Jun 2026
Recent insider transactions for Passage BIO, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share ("Common Stock") | Purchase | 8.03% | $206,101 | $4.12 | 50,055 | 673,759 | 25 Jun 2026 | See footnote |
| Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share ("Common Stock") | Purchase | 8.03% | $206,101 | $4.12 | 50,055 | 673,759 | 25 Jun 2026 | See footnote |
| Dolan Sondhi | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Derrell Porter | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Thomas Richard Kassberg | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Sandip Kapadia | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Maxine Gowen | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Athena Countouriotis | PASG | Director Stock Option (right to buy) | Award | 10,539 | 10,539 | 19 May 2026 | Direct | |||
| Kathleen Borthwick | PASG | Employee Stock Option (right to buy) | Award | 15,610 | 15,610 | 16 Mar 2026 | Direct | |||
| William Chou | PASG | Employee Stock Option (right to buy) | Award | 58,000 | 58,000 | 16 Mar 2026 | Direct | |||
| William Chou | PASG | Common Stock | Sale | -38.4% | -4,076 | 6,524 | 08 Jan 2026 | Direct | ||
| William Chou | PASG | Common Stock | Options Exercise | 1666.7% | 10,000 | 10,600 | 08 Jan 2026 | Direct | ||
| William Chou | PASG | Restricted Stock Unit | Options Exercise | -50% | -10,000 | 10,000 | 08 Jan 2026 | Direct | ||
| Kathleen Borthwick | PASG | Common Stock | Sale | -27.6% | -2,062 | 5,402 | 08 Jan 2026 | Direct | ||
| Kathleen Borthwick | PASG | Common Stock | Options Exercise | 202.9% | 5,000 | 7,464 | 08 Jan 2026 | Direct | ||
| Kathleen Borthwick | PASG | Restricted Stock Unit | Options Exercise | -50% | -5,000 | 5,000 | 08 Jan 2026 | Direct | ||
| Lynx1 Capital Management LP | PASG | Common Stock | Purchase | 1.95% | $83,175 | $6.99 | 11,900 | 623,704 | 15 Sep 2025 | See footnote |
| Lynx1 Capital Management LP | PASG | Common Stock | Purchase | 3.34% | $138,299 | $6.99 | 19,783 | 611,804 | 12 Sep 2025 | See footnote |
| Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share (Common Stock) | Purchase | 0.05% | $2,261 | $6.96 | 325 | 592,021 | 11 Sep 2025 | See footnote |
* marks a reported price that did not pass the local price check.